Alector Inc
$ 1.51
-6.79%
31 Jul - close price
- Market Cap 167,648,000 USD
- Current Price $ 1.51
- High / Low $ 1.62 / 1.49
- Stock P/E N/A
- Book Value 0.09
- EPS -1.19
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -2.39 %
- 52 Week High 3.40
- 52 Week Low 1.09
About
Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases. The company is headquartered in South San Francisco, California.
Analyst Target Price
$3.10
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-25 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-26 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-02-27 | 2023-11-07 | 2023-08-03 |
| Reported EPS | -0.21 | -0.34 | -0.34 | -0.3 | -0.41 | -0.02 | -0.43 | -0.4 | -0.38 | -0.49 | -0.53 | 0.02 |
| Estimated EPS | -0.27 | -0.3913 | -0.41 | -0.45 | -0.46 | -0.5443 | -0.53 | -0.48 | -0.49 | -0.77 | -0.65 | -0.82 |
| Surprise | 0.06 | 0.0513 | 0.07 | 0.15 | 0.05 | 0.5243 | 0.1 | 0.08 | 0.11 | 0.28 | 0.12 | 0.84 |
| Surprise Percentage | 22.2222% | 13.1101% | 17.0732% | 33.3333% | 10.8696% | 96.3256% | 18.8679% | 16.6667% | 22.449% | 36.3636% | 18.4615% | 102.439% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.24 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALEC
2026-08-02 04:40:15
This article provides a detailed financial overview of Alector Inc. (ALEC), including its latest earnings report, key financial indicators like EPS, revenue, net profit, and balance sheet details. It also includes an analyst rating of "HOLD" and answers frequently asked questions regarding the company's financial performance in FY2025.
2026-08-01 19:40:15
Alector Inc (0Z2) released its Q4 2022 earnings report, missing both EPS and revenue expectations. The company reported an actual EPS of -€0.55 against a consensus of -€0.40 and actual revenue of €12.52M compared to an expected €26.13M. Alector's next earnings date is estimated for November 10, 2026.
2026-08-01 07:39:19
This article provides a financial snapshot for Alector, Inc. (NASDAQ: ALEC), focusing on its enterprise value to EBITDA forward. It details that the market for Alector, Inc. is currently closed with no trades. The content is primarily a data presentation from TradingView, with disclaimers about market and reference data providers.
2026-08-01 06:10:35
Alector Inc (0Z2) reported its Q4 2023 earnings, beating both EPS and revenue expectations. The company posted an actual EPS of -€0.42 against a consensus of -€0.67, and actual revenue of €13.17M versus an expected €7.66M, representing a YoY revenue growth of +5.19%. The earnings call took place on February 27, 2024, and the next earnings report is estimated for November 10, 2026.
2026-07-30 12:11:31
Alector (ALEC) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 6th, with analysts forecasting a loss of $0.24 per share and revenue of $1.43 million. This follows a Q1 report where the company beat EPS estimates but significantly missed revenue expectations. Despite a consensus "Hold" rating, analysts project full-year losses of approximately $1 per share, and recent insider selling has also been noted.
2026-07-30 06:40:22
Alector Inc (ALEC) has received an overall TradingKey Stock Score of 5.79/10, indicating stable fundamentals and significant growth potential, although its valuation is considered fairly valued. Institutional ownership is very high, and analysts have recently rated the stock as "Hold" with a target price of $3.10. The company, a clinical-stage biotechnology firm focused on neurodegenerative diseases, is in a growing phase but faces risks such as being overvalued and institutional selling.
